Literature DB >> 16049639

Elimination kinetics of L-alanyl-L-glutamine in ICU patients.

A Berg1, O Rooyackers, A Norberg, J Wernerman.   

Abstract

A randomised, double blind, placebo-controlled study was performed giving 0.5 g x kg(-1) x day(-1) of undiluted alanyl-glutamine (20%) or saline in a peripheral vein during 4 hours in ICU patients (n = 20). During the infusion period a steady state in plasma concentration was reached for alanyl-glutamine, but not for alanine, glutamine or glutamate. On the other hand there was no accumulation of any of the amino acids, as the pre-infusion concentrations were reached within 8 hours after the end of infusion. The half-life of the dipeptide was 0.26 hours (range, 0.15-0.63 h). The distribution volume of alanyl-glutamine was larger than the extracellular water volume, indicating a rapid hydrolysis of the dipeptide. There was no detectable alanyl-glutamine in the urine of any of the patients. All patients had excretion of small amounts of amino acids in urine, but the renal clearance of alanine, glutamine and glutamate were not different between the two groups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16049639     DOI: 10.1007/s00726-005-0230-9

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  11 in total

1.  New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition.

Authors:  Gamze Akbulut
Journal:  Exp Ther Med       Date:  2011-04-01       Impact factor: 2.447

2.  Glutamine supplementation.

Authors:  Jan Wernerman
Journal:  Ann Intensive Care       Date:  2011-07-18       Impact factor: 6.925

3.  Glutamine kinetics during intravenous glutamine supplementation in ICU patients on continuous renal replacement therapy.

Authors:  A Berg; A Norberg; C-R Martling; L Gamrin; O Rooyackers; J Wernerman
Journal:  Intensive Care Med       Date:  2007-02-22       Impact factor: 17.440

4.  Glutamine and glutathione at ICU admission in relation to outcome.

Authors:  Paul Castillo Rodas; Olav Rooyackers; Christina Hebert; Åke Norberg; Jan Wernerman
Journal:  Clin Sci (Lond)       Date:  2012-06       Impact factor: 6.124

Review 5.  Glutamine supplementation to critically ill patients?

Authors:  Jan Wernerman
Journal:  Crit Care       Date:  2014-03-18       Impact factor: 9.097

6.  Endogenous glutamine production in critically ill patients: the effect of exogenous glutamine supplementation.

Authors:  Maiko Mori; Olav Rooyackers; Marie Smedberg; Inga Tjäder; Ake Norberg; Jan Wernerman
Journal:  Crit Care       Date:  2014-04-14       Impact factor: 9.097

7.  Prolonged continuous intravenous infusion of the dipeptide L-alanine- L-glutamine significantly increases plasma glutamine and alanine without elevating brain glutamate in patients with severe traumatic brain injury.

Authors:  Mirjam Nägeli; Mario Fasshauer; Jutta Sommerfeld; Angela Fendel; Giovanna Brandi; John F Stover
Journal:  Crit Care       Date:  2014-07-02       Impact factor: 9.097

8.  Plasma glutamine concentration after intensive care unit discharge: an observational study.

Authors:  Marie Smedberg; Johanna Nordmark Grass; Linn Pettersson; Åke Norberg; Olav Rooyackers; Jan Wernerman
Journal:  Crit Care       Date:  2014-12-09       Impact factor: 9.097

9.  A commentary on the 2015 Canadian Clinical Practice Guidelines in glutamine supplementation to parenteral nutrition.

Authors:  Alberto Leguina-Ruzzi
Journal:  Crit Care       Date:  2016-01-08       Impact factor: 9.097

Review 10.  Is the glutamine story over?

Authors:  Marie Smedberg; Jan Wernerman
Journal:  Crit Care       Date:  2016-11-10       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.